These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25394209)

  • 41. Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.
    Cicha A; Fischer MB; Wesinger A; Haas S; Bauer WM; Wolf HM; Sauerwein KMT; Reininger B; Petzelbauer P; Pehamberger H; Handisurya A
    J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):1004-1010. PubMed ID: 29114967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations.
    Terryberry JW; Shoenfeld Y; Sherer Y; Levy Y; Fabrizzi F; Ahmed A; Peter JB
    Immunol Invest; 2000 Aug; 29(3):337-47. PubMed ID: 10933614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.
    Dimitriadou MM; Alexopoulos H; Akrivou S; Gola E; Dalakas MC
    Neurotherapeutics; 2020 Jan; 17(1):235-242. PubMed ID: 31673865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy.
    Nakano Y; Hayashi T; Deguchi K; Sato K; Hishikawa N; Yamashita T; Ohta Y; Takao Y; Morio T; Abe K
    J Neurol Sci; 2016 Feb; 361():9-12. PubMed ID: 26810508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-Rh D activity of commercial intravenous immunoglobulin preparations.
    Turner CE; Thorpe SJ; Brasher MD; Thorpe R
    Vox Sang; 1999; 76(1):55-8. PubMed ID: 9933855
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fatigue and the wear-off effect in adult patients with common variable immunodeficiency.
    Hajjar J; Kutac C; Rider NL; Seeborg FO; Scalchunes C; Orange J
    Clin Exp Immunol; 2018 Dec; 194(3):327-338. PubMed ID: 30168848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.
    Kaveri SV; Maddur MS; Hegde P; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):2-5. PubMed ID: 21466545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation of Natural Anti-FcεRIα Autoantibodies from Healthy Donors.
    Vogel M; Horn MP
    Methods Mol Biol; 2017; 1643():5-22. PubMed ID: 28667526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity.
    Thorpe SJ; Fox BJ; Dolman CD; Lawrence J; Thorpe R
    Vox Sang; 2003 Aug; 85(2):80-4. PubMed ID: 12925158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.
    Artac H; Kara R; Reisli I
    Clin Exp Med; 2010 Mar; 10(1):27-31. PubMed ID: 19730984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIG therapy in CVID.
    Mushiake K; Motoyoshi F; Kondo N; Shimizu H; Orii T
    Biotherapy; 1993-1994; 7(2):101-7. PubMed ID: 7803189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous immunoglobulin replacement treatment does not alter polymorphonuclear leukocytes function and surface receptors expression in patients with common variable immunodeficiency.
    Prezzo A; Cavaliere FM; Bilotta C; Iacobini M; Quinti I
    Cell Immunol; 2016; 306-307():25-34. PubMed ID: 27264689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications.
    Welsh KJ; Bai Y
    J Clin Apher; 2015 Dec; 30(6):371-4. PubMed ID: 26123478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inpatient Rheumatology Consultation Prompted by Positive Autoantibodies in Patients Receiving Intravenous Immunoglobulin Therapy: A Case Series and Literature Review.
    Fnu Z; Uddin A; Navetta-Modrov B; Patnaik A; Kaell A
    Cureus; 2023 Apr; 15(4):e37008. PubMed ID: 37020710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.
    Grüter T; Ott A; Meyer W; Jarius S; Kinner M; Motte J; Pitarokoili K; Gold R; Komorowski L; Ayzenberg I
    J Neurol; 2020 Mar; 267(3):715-720. PubMed ID: 31728710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse effects of intravenous immunoglobulin.
    Misbah SA; Chapel HM
    Drug Saf; 1993 Oct; 9(4):254-62. PubMed ID: 8260119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemolytic anemia associated with intravenous immunoglobulin.
    Wilson JR; Bhoopalam H; Fisher M
    Muscle Nerve; 1997 Sep; 20(9):1142-5. PubMed ID: 9270670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphocytic interstitial pneumonia associated with common variable immunodeficiency resolved with intravenous immunoglobulins.
    Arish N; Eldor R; Fellig Y; Bogot N; Laxer U; Izhar U; Rokach A
    Thorax; 2006 Dec; 61(12):1096-7. PubMed ID: 17114373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression.
    Paquin-Proulx D; Sandberg JK
    Front Immunol; 2014; 5():637. PubMed ID: 25566250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG).
    Graeter S; Simon HU; von Gunten S
    Pharmacol Res; 2020 Apr; 154():104168. PubMed ID: 30738127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.